NEWRON PHARMACEUTICALS SPA (NP5.DE) Stock Overview
Europe - FRA:NP5 - IT0004147952 - Common Stock
NP5.DE Key Statistics, Chart & Performance
The current stock price of NP5.DE is 11.12 EUR. In the past month the price increased by 37.11%. In the past year, price increased by 32.54%.
NP5.DE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY.DE | ELI LILLY & CO | 46.89 | 610.66B | ||
| 1LLY.MI | ELI LILLY & CO | 46.82 | 609.71B | ||
| ZEG.DE | ASTRAZENECA PLC | 17.29 | 403.22B | ||
| JNJ.DE | JOHNSON & JOHNSON | 17.55 | 360.09B | ||
| RHO.DE | ROCHE HOLDING AG-BR | 14.06 | 239.54B | ||
| NOV.DE | NOVO NORDISK A/S-B | 15.54 | 230.70B | ||
| NOT.DE | NOVARTIS AG-REG | 14.05 | 202.65B | ||
| SNW.DE | SANOFI | 10.69 | 196.77B | ||
| SAN.PA | SANOFI | 10.66 | 196.24B | ||
| 1SAN.MI | SANOFI | 10.59 | 194.92B | ||
| 6MK.DE | MERCK & CO. INC. | 10.58 | 173.35B | ||
| 1MRKX.MI | MERCK & CO. INC. | 10.5 | 172.60B |
Related stock screener links
About NP5.DE
Company Profile
Newron Pharmaceuticals SpA operates as a biopharmaceutical company. The company is headquartered in Bresso, Milano and currently employs 22 full-time employees. The company went IPO on 2006-12-12. The company focuses on the discovery and development of pharmaceutical products. The firm is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The firm undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson’s disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Its additional projects, such as HF0220 for neuroprotection, NW-3509 for the treatment of schizophrenia, as well as pruvanserin and sarizotan for treatment of CNS diseases, are at various stages of preclinical and clinical development.
Company Info
NEWRON PHARMACEUTICALS SPA
via Antonio Meucci 3
Bresso MILANO IT
Employees: 22
Phone: 39026103461
NEWRON PHARMACEUTICALS SPA / NP5.DE FAQ
What is the stock price of NEWRON PHARMACEUTICALS SPA today?
The current stock price of NP5.DE is 11.12 EUR. The price increased by 0.54% in the last trading session.
What is the ticker symbol for NEWRON PHARMACEUTICALS SPA stock?
The exchange symbol of NEWRON PHARMACEUTICALS SPA is NP5 and it is listed on the Deutsche Boerse Ag exchange.
On which exchange is NP5.DE stock listed?
NP5.DE stock is listed on the Deutsche Boerse Ag exchange.
What is the price forecast or stock price prediction for NEWRON PHARMACEUTICALS SPA stock?
8 analysts have analysed NP5.DE and the average price target is 18.11 EUR. This implies a price increase of 62.86% is expected in the next year compared to the current price of 11.12. Check the NEWRON PHARMACEUTICALS SPA stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is NEWRON PHARMACEUTICALS SPA worth?
NEWRON PHARMACEUTICALS SPA (NP5.DE) has a market capitalization of 221.96M EUR. This makes NP5.DE a Micro Cap stock.
How many employees does NEWRON PHARMACEUTICALS SPA have?
NEWRON PHARMACEUTICALS SPA (NP5.DE) currently has 22 employees.
What are the support and resistance levels for NEWRON PHARMACEUTICALS SPA (NP5.DE) stock?
NEWRON PHARMACEUTICALS SPA (NP5.DE) has a support level at 11.08 and a resistance level at 11.13. Check the full technical report for a detailed analysis of NP5.DE support and resistance levels.
Is NEWRON PHARMACEUTICALS SPA (NP5.DE) expected to grow?
The Revenue of NEWRON PHARMACEUTICALS SPA (NP5.DE) is expected to decline by -74.52% in the next year. Check the estimates tab for more information on the NP5.DE EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy NEWRON PHARMACEUTICALS SPA (NP5.DE) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of NP5.DE, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of NP5.DE, evaluating the profitability, health, valuation and growth aspects
- NEWRON PHARMACEUTICALS SPA (NP5.DE) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- NEWRON PHARMACEUTICALS SPA (NP5.DE) Sales and EPS estimates to see what analysts future expectations are.
- NEWRON PHARMACEUTICALS SPA (NP5.DE) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- NEWRON PHARMACEUTICALS SPA (NP5.DE) Insider and Institutional Ownership to learn about the owners and their transactions.
- NEWRON PHARMACEUTICALS SPA (NP5.DE) Stock Chart to make your own analysis
- NEWRON PHARMACEUTICALS SPA (NP5.DE) Latest news and press-releases to stay up to date.
Does NEWRON PHARMACEUTICALS SPA (NP5.DE) stock pay dividends?
NP5.DE does not pay a dividend.
What is the Price/Earnings (PE) ratio of NEWRON PHARMACEUTICALS SPA (NP5.DE)?
The PE ratio for NEWRON PHARMACEUTICALS SPA (NP5.DE) is 13.08. This is based on the reported non-GAAP earnings per share of 0.85 and the current share price of 11.12 EUR. Check the full fundamental report for a full analysis of the valuation metrics for NP5.DE.
NP5.DE Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to NP5.DE. When comparing the yearly performance of all stocks, NP5.DE is one of the better performing stocks in the market, outperforming 91% of all stocks.
NP5.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to NP5.DE. NP5.DE has only an average score on both its financial health and profitability.
NP5.DE Financial Highlights
Over the last trailing twelve months NP5.DE reported a non-GAAP Earnings per Share(EPS) of 0.85. The EPS increased by 193.41% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 30.83% | ||
| ROA | 24.79% | ||
| ROE | 1086.63% | ||
| Debt/Equity | 25.32 |
NP5.DE Forecast & Estimates
8 analysts have analysed NP5.DE and the average price target is 18.11 EUR. This implies a price increase of 62.86% is expected in the next year compared to the current price of 11.12.
For the next year, analysts expect an EPS growth of -231.2% and a revenue growth -74.52% for NP5.DE